Advertisement

Moscow University Chemistry Bulletin

, Volume 71, Issue 5–6, pp 287–294 | Cite as

Cryochemical modification of drugs: Nanosized form III piroxicam and its physical and chemical properties

  • Yu. N. Morozov
  • V. V. Fedorov
  • V. P. Shabatin
  • O. I. Vernaya
  • V. V. Chernyshev
  • A. S. Abel
  • I. V. Arhangel’skii
  • T. I. Shabatina
  • G. B. Sergeev
Article

Abstract

Dynamic sublimation in a stream of heated carrier gas and low-temperature condensation are used to perform structural and dimensional modification of nonsteroidal anti-inflammatory preparation of 4-hydroxy-2-methyl-N-(2-pyridinyl)-2Н-1,2-benzothiazin-3-carboxamide 1,1-dioxide (piroxicam) and to obtain its nanoscale form. Thus obtained samples correspond to the known thermodynamically metastable Form III of the compound. The average particle size of the preparation is d av = 300 ± 30 nm. The resulting nanosized form of piroxicam is relatively stable with respect to structural and dimensional transformations for at least four years.

Keywords

organic nanoparticles cryochemical modification polymorphism of pharmaceutical preparations piroxicam 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lipinski, C., Am. Pharm. Rev., 2002, vol. 5, p. 82.Google Scholar
  2. 2.
    Reck, G., Dietz, G., Laban, G., Gunther, W., Bannier, G., and Hohne, E., Pharmazie, 1988, vol. 43, p. 477.Google Scholar
  3. 3.
    Vreĉer, F., Vrbinc, M., and Meden, A., Int. J. Pharm., 2003, vol. 256, p. 3.CrossRefGoogle Scholar
  4. 4.
    Sheth, A.R., Lubach, J.W., Munson, E.J., Muller, F.X., and Grant, D.J.W., J. Am. Chem. Soc., 2005, vol. 127, p. 1241.CrossRefGoogle Scholar
  5. 5.
    Kojic-Prodic, B. and Ruzic-Toros, Z., Acta Crystallogr. Sect. B: Struct. Crystallogr. Cryst. Chem., 1982, vol. 38, p. 2948.CrossRefGoogle Scholar
  6. 6.
    Naelapää, K., Van De Streek, J., Rantanen, J., and Bond, A.D., J. Pharm. Sci., 2012, vol. 101, no. 11, p. 4214.CrossRefGoogle Scholar
  7. 7.
    Vreĉer, F., Srčič, S., and Šmid-Korbar, J., Int. J. Pharm., 1991, vol. 68, p. 35.CrossRefGoogle Scholar
  8. 8.
    Lavrič, Z., Pirnat, J., Lužnic, J., Puc, U., Trontelj, Z., and Srčič, S., J. Pharm. Sci., 2015, vol. 104, p. 1909.CrossRefGoogle Scholar
  9. 9.
    Nystrom, M., Roine, J., Murtomaa, M., Sankaran, R.M., Santos, H.A., and Salonen, J., Eur. J. Pharm. Biopharm., 2015, vol. 89, p. 182.CrossRefGoogle Scholar
  10. 10.
    Bordner, J., Richards, J.A., Weeks, P., and Whipple, E.B., Acta Crystallogr., Sect. C: Cryst. Struct. Commun., 1984, vol. 40, p. 989.CrossRefGoogle Scholar
  11. 11.
    Sheth, A.R., Bates, S., Muller, F.X., and Grant, D.J.W., Cryst. Growth Des., 2004, vol. 4, no. 6, p. 1091.CrossRefGoogle Scholar
  12. 12.
    Shakhtshneider, T.P., Myz, S.A., Dyakonova, M.A., Boldyrev, V.V., Boldyreva, E.V., Nizovskii, A.I., Kalinkin, A.V., and Kumar, R., Acta Phys. Pol., 2011, vol. 120, no. 2, p. 272.CrossRefGoogle Scholar

Copyright information

© Allerton Press, Inc. 2016

Authors and Affiliations

  • Yu. N. Morozov
    • 1
  • V. V. Fedorov
    • 1
    • 2
  • V. P. Shabatin
    • 1
  • O. I. Vernaya
    • 1
  • V. V. Chernyshev
    • 1
  • A. S. Abel
    • 1
  • I. V. Arhangel’skii
    • 1
  • T. I. Shabatina
    • 1
    • 2
  • G. B. Sergeev
    • 1
  1. 1.Department of ChemistryMoscow State UniversityMoscowRussia
  2. 2.Bauman Moscow State Technical UniversityMoscowRussia

Personalised recommendations